Low programmed cell death-1 (PD-1) expression in peripheral CD4+ T cells in Japanese patients with autoimmune type 1 diabetes

Clinical and Experimental Immunology

Volumn 180, Issue 3, 2015, Pages 452-457

  Fujisawa, R ^a   Haseda, F ^a   Tsutsumi, C ^a   Hiromine, Y ^b   Noso, S ^b   Kawabata, Y ^b   Mitsui, S ^a   Terasaki, J ^a   Ikegami, H ^b   Imagawa, A ^a,c   Hanafusa, T ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Fulminant type 1 diabetes; PD 1; Type 1A diabetes

Indexed keywords

CD4 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; MESSENGER RNA; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; JAPANESE (PEOPLE); MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; ADOLESCENT; ALLELE; CASE CONTROL STUDY; GENE EXPRESSION; GENETICS; IMMUNOLOGY; JAPAN; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALLELES; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION; GENOTYPE; HUMANS; JAPAN; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; RNA, MESSENGER; YOUNG ADULT;

EID: 84929337772     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12603     Document Type: Article

References (37)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014; 37 (Suppl. 1):S81-90.
2. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539-53.
3. Seino Y, Nanjo K, Tajima N et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1:212-28.
4. Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986; 314:1360-8.
5. Roep BO. The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure. Diabetologia 2003; 46:305-21.
6. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965; 14:619-33.
7. Bottazzo GF, Dean BM, McNally JM, MacKay EH, Swift PG, Gamble DR. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 1985; 313:353-60.
8. Hawkes CJ, Schloot NC, Marks J et al. T-cell lines reactive to an immunodominant epitope of the tyrosine phosphatase-like autoantigen IA-2 in type 1 diabetes. Diabetes 2000; 49:356-66.
9. Nagata M, Kotani R, Moriyama H, Yokono K, Roep BO, Peakman M. Detection of autoreactive T cells in type 1 diabetes using coded autoantigens and an immunoglobulin-free cytokine ELISPOT assay: report from the fourth immunology of diabetes society T cell workshop. Ann NY Acad Sci 2004; 1037:10-5.
10. Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM study group. N Engl J Med 2000; 342:301-7.
11. Imagawa A, Hanafusa T, Uchigata Y et al. Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care 2003; 26:2345-52.
12. Tanaka S, Kobayashi T, Momotsu T. A novel subtype of type 1 diabetes mellitus. N Engl J Med 2000; 342:1835-7.
13. Shibasaki S, Imagawa A, Tauriainen S et al. Expression of Toll-like receptors in the pancreas of recent-onset fulminant type 1 diabetes. Endocr J 2010; 57:211-9.
14. Okazaki T, Iwai Y, Honjo T. New regulatory co-receptors: inducible co-stimulator and PD-1. Curr Opin Immunol 2002; 14:779-82.
15. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23:515-48.
16. Parry RV, Chemnitz JM, Frauwirth KA et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005; 25:9543-53.
17. Wang J, Yoshida T, Nakaki F, Hiai H, Okazaki T, Honjo T. Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci USA 2005; 102:11823-8.
18. Pauken KE, Jenkins MK, Azuma M, Fife BT. PD-1, but not PD-L1, expressed by islet-reactive CD4+ T cells suppresses infiltration of the pancreas during type 1 diabetes. Diabetes 2013; 62:2859-69.
19. Todd JA. Etiology of type 1 diabetes. Immunity 2010; 32:457-67.
20. Nielsen C, Hansen D, Husby S, Jacobsen BB, Lillevang ST. Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens 2003; 62:492-7.
21. Ni R, Ihara K, Miyako K et al. PD-1 gene haplotype is associated with the development of type 1 diabetes mellitus in Japanese children. Hum Genet 2007; 121:223-32.
22. Hiromine Y, Ikegami H, Fujisawa T et al. Trinucleotide repeats of programmed cell death-1 gene are associated with susceptibility to type 1 diabetes mellitus. Metabolism 2007; 56:905-9.
23. Momin S, Flores S, Angel B B, Codner D E, Carrasco P E, Perez-Bravo F. Interactions between programmed death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) gene polymorphisms in type 1 diabetes. Diabetes Res Clin Pract 2009; 83:289-94.
24. Asad S, Nikamo P, Törn C et al. No evidence of association of the PDCD1 gene with Type 1 diabetes. Diabet Med 2007; 24:1473-7.
25. Cooper JD, Smyth DJ, Bailey R et al. The candidate genes TAF5L, TCF7, PDCD1, IL6 and ICAM1 cannot be excluded from having effects in type 1 diabetes. BMC Med Genet 2007; 8:71.
26. Flores S, Beems M, Oyarzún A, Carrasco E, Pérez F. Programmed cell death 1 (PDCD1) gene polymorphisms and type 1 diabetes in Chilean children. Rev Med Chil 2010; 138:543-50.
27. Lee YH, Bae SC, Kim JH, Song GG. Meta-analysis of genetic polymorphisms in programmed cell death 1: Associations with rheumatoid arthritis, ankylosing spondylitis, and type 1 diabetes susceptibility. Z Rheumatol 2014 [Epub ahead of print].
28. Hanafusa T, Imagawa A. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Pract Endocrinol Metab 2007; 3:36-45.
29. Kashiwagi A, Kasuga M, Araki E et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to national glycohemoglobin standardization program values. J Diabetes Invest 2012; 3:39-40.
30. + T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. J Rheumatol 2003; 30:1410-9.
31. + T cells and correlation with the PD-1.3A genotype in patients with systemic lupus erythematosus. Arthritis Rheum 2010; 62:1702-11.
32. Trabattoni D, Saresella M, Pacei M et al. Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. J Immunol 2009; 183:4984-93.
33. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11:141-51.
34. Nishimura H, Okazaki T, Tanaka Y et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001; 291:319-22.
35. Prokunina L, Castillejo-López C, Oberg F et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002; 32:666-9.
36. Lin SC, Yen JH, Tsai JJ et al. Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum 2004; 50:770-5.
37. + helper T-cells in patients with fulminant type 1 diabetes. Immunol Lett 2011; 139:80-6.